PRLD Prelude Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PRLD

Price (delayed)

$3.99

Market cap

$219.13M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.02

Enterprise value

$206.69M

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective ...

Highlights
The equity rose by 21% year-on-year
The EPS has increased by 17% year-on-year and by 7% since the previous quarter
The quick ratio has contracted by 22% from the previous quarter but it has grown by 15% YoY
Prelude Therapeutics's net income has decreased by 6% YoY and by 3.8% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://preludetx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of PRLD
Market
Shares outstanding
54.92M
Market cap
$219.13M
Enterprise value
$206.69M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.92
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$121.83M
EBITDA
-$118.73M
Free cash flow
-$110.58M
Per share
EPS
-$2.02
Free cash flow per share
-$1.83
Book value per share
$4.32
Revenue per share
$0
TBVPS
$4.6
Balance sheet
Total assets
$277.67M
Total liabilities
$40.58M
Debt
$16.89M
Equity
$237.09M
Working capital
$213.76M
Liquidity
Debt to equity
0.07
Current ratio
10.79
Quick ratio
10.86
Net debt/EBITDA
0.1
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-48%
Return on equity
-53.4%
Return on invested capital
-56.7%
Return on capital employed
-47.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PRLD stock price

How has the Prelude Therapeutics stock price performed over time
Intraday
0%
1 week
-1.97%
1 month
-15.47%
1 year
-37.26%
YTD
-6.56%
QTD
-15.82%

Financial performance

How have Prelude Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$132.28M
Net income
-$121.83M
Gross margin
N/A
Net margin
N/A
PRLD's operating income is down by 7% year-on-year and by 3.1% since the previous quarter
Prelude Therapeutics's net income has decreased by 6% YoY and by 3.8% QoQ

Growth

What is Prelude Therapeutics's growth rate over time

Valuation

What is Prelude Therapeutics stock price valuation
P/E
N/A
P/B
0.92
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 17% year-on-year and by 7% since the previous quarter
The equity rose by 21% year-on-year
The stock's P/B is 8% below its last 4 quarters average of 1.0

Efficiency

How efficient is Prelude Therapeutics business performance
Prelude Therapeutics's ROIC has increased by 10% YoY and by 6% from the previous quarter
PRLD's return on equity is down by 6% year-on-year
The ROA has contracted by 4.1% YoY but it has grown by 2% from the previous quarter

Dividends

What is PRLD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PRLD.

Financial health

How did Prelude Therapeutics financials performed over time
PRLD's total liabilities has soared by 100% from the previous quarter and by 62% YoY
The total assets has grown by 26% year-on-year and by 7% since the previous quarter
The debt is 93% lower than the equity
The equity rose by 21% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.